Prospective trial finds robotic surgery a safe option for right-sided colon cancer

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

A prospective, open-label, single-arm phase 2 trial conducted at two institutions in Japan (the ROBOCOLO trial) evaluated the safety of robotic-assisted surgery for resectable, stage I-III right-sided colon cancer. Between August 2021 and February 2023, 42 patients were enrolled; 39 were included in the full analysis after 3 exclusions. The trial’s primary endpoint — the postoperative complication rate within 30 days of surgery — supported the safety of the robotic approach in this population, published in the Annals of Gastroenterological Surgery (DOI 10.1002/ags3.12718). This is a single-arm feasibility/safety trial, not a randomized comparison against conventional laparoscopic or open surgery, and this record makes no claim that robotic surgery produces better cancer outcomes (survival, recurrence) than those alternatives — that would require a larger, randomized, longer-follow-up trial.

What This Means

In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as a safe option for this procedure in the 39 patients analyzed.

What This Doesn't Mean

This is a single-arm feasibility/safety trial with no randomized comparison group -- it does NOT establish that robotic surgery produces better cancer outcomes (survival, recurrence) than conventional laparoscopic or open surgery for this indication. That would require a larger, randomized, longer-follow-up trial.

Why It Matters

Real, prospective safety data on robotic surgery for a specific, common cancer procedure gives patients and surgeons genuine evidence to weigh, in a topic area -- surgical advances -- that had no real content on this site before this record.

Promise & Proof

Proof — strength of the evidence 4 / 5
  • Base score from evidence stage: Later-Stage Human.
Promise — potential significance if later evidence holds up 2 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with resectable, stage I-III right-sided colon cancer, enrolled in the prospective, open-label, single-arm, phase 2 ROBOCOLO trial at two institutions in Japan. (Adults)

A small (39-patient), single-institution-pair feasibility trial -- not yet broad, multi-center confirmatory evidence. This record has not independently reviewed the full complication/adverse-event data, which should be added before publication.

Full evidence details
Study design
Non-randomized trial
Sample size
39

Funding & Conflicts

Reported academic/institutional origin (two Japanese institutions) -- not independently confirmed against a primary grant-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

Prospective trial finds robotic surgery a safe option for right-sided colon cancer

https://cancerdiscoveries.com/discoveries/prospective-trial-finds-robotic-surgery-a-safe-option-for-right-sided-colon-cancer/

Evidence stage: Later-Stage Human

What This Means

In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as a safe option for this procedure in the 39 patients analyzed.

What This Doesn't Mean

This is a single-arm feasibility/safety trial with no randomized comparison group -- it does NOT establish that robotic surgery produces better cancer outcomes (survival, recurrence) than conventional laparoscopic or open surgery for this indication. That would require a larger, randomized, longer-follow-up trial.

Why It Matters

Real, prospective safety data on robotic surgery for a specific, common cancer procedure gives patients and surgeons genuine evidence to weigh, in a topic area -- surgical advances -- that had no real content on this site before this record.

Primary sources

  • Surgical outcomes of a prospective, phase 2 trial of robotic surgery for resectable right-sided colon cancer (the ROBOCOLO trial) (Annals of Gastroenterological Surgery) — https://doi.org/10.1002/ags3.12718 (DOI 10.1002/ags3.12718)

Date verified: 2026-08-13

Correction status: No correction or retraction